{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Common non-SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, other medical events according to medical or scientific judgement and all events of possible study treatment-induced liver injury with hyperbilirubinemia. Part 2 NHL Population comprised of all Part 2 NHL participants who received at least one dose of GSK2857916. SAEs and common (\\>=5%) non-SAEs is presented.","groups":[{"description":"Participants with non-hodgkin's lymphoma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 36 cycles (1 cycle=21 days)","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (NHL)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part 2 NHL Population","reportingStatus":"POSTED","timeFrame":"Up to 7.2 months (maximum duration of follow-up from first dose to last contact or death)","title":"Number of Participants With SAEs and Common (>=5%) Non-serious Adverse Events- Part 2 (NHL)","type":"PRIMARY","unitOfMeasure":"Participants"}